Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia

Banu Arun, Brendan D. Curti, Dan L. Longo, Diane Stevens, W. Gregory Alvord, Barry L. Gause, Thelma Watson, William C. Kopp, John Edward Janik

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

PURPOSE: Interferon-alfa, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine (2-CdA) are effective in the management of patients with hairy cell leukemia. These agents produce remissions in most patients, but relapses occur with all three drugs. The optimal means to follow patients for relapse after treatment has not been determined. METHODS: We retrospectively examined serial serum soluble interleukin-2 receptor levels (sIL-2R) and absolute granulocyte counts in eight patients with relapsed hairy cell leukemia. All were treated with 2-CdA at the time of relapse. Serum samples were available at 3- to 6- month intervals from 5 to 9 years before relapse and 2-CdA treatment. RESULTS: sIL-2R levels increase only in patients who go on to relapse, sIL-2R levels doubled a mean of 17.1 months (range, 4-36 months) before absolute granulocyte count decreased by 50%. DISCUSSION: Demonstration of a rising serum sIL-2R level in patients with hairy cell leukemia identified those with an increased risk of relapse who need more frequent observation than patients who maintain a stable sIL-2R level. Early intervention may ameliorate the toxicity of salvage therapy because disease-related neutropenia may be anticipated.

Original languageEnglish (US)
Pages (from-to)21-24
Number of pages4
JournalCancer Journal from Scientific American
Volume6
Issue number1
StatePublished - Jan 1 2000

Fingerprint

Hairy Cell Leukemia
Interleukin-2 Receptors
Recurrence
Cladribine
Serum
Granulocytes
Pentostatin
Salvage Therapy
Neutropenia
Interferon-alpha
Observation
Therapeutics
Pharmaceutical Preparations

Keywords

  • Disease progression
  • Follow-up study
  • Human
  • Lymphoproliferative malignancy
  • Neutropenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Arun, B., Curti, B. D., Longo, D. L., Stevens, D., Alvord, W. G., Gause, B. L., ... Janik, J. E. (2000). Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer Journal from Scientific American, 6(1), 21-24.

Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. / Arun, Banu; Curti, Brendan D.; Longo, Dan L.; Stevens, Diane; Alvord, W. Gregory; Gause, Barry L.; Watson, Thelma; Kopp, William C.; Janik, John Edward.

In: Cancer Journal from Scientific American, Vol. 6, No. 1, 01.01.2000, p. 21-24.

Research output: Contribution to journalArticle

Arun, B, Curti, BD, Longo, DL, Stevens, D, Alvord, WG, Gause, BL, Watson, T, Kopp, WC & Janik, JE 2000, 'Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia', Cancer Journal from Scientific American, vol. 6, no. 1, pp. 21-24.
Arun, Banu ; Curti, Brendan D. ; Longo, Dan L. ; Stevens, Diane ; Alvord, W. Gregory ; Gause, Barry L. ; Watson, Thelma ; Kopp, William C. ; Janik, John Edward. / Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. In: Cancer Journal from Scientific American. 2000 ; Vol. 6, No. 1. pp. 21-24.
@article{8e6f4b2c77ba465e9107fb555661ddd1,
title = "Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia",
abstract = "PURPOSE: Interferon-alfa, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine (2-CdA) are effective in the management of patients with hairy cell leukemia. These agents produce remissions in most patients, but relapses occur with all three drugs. The optimal means to follow patients for relapse after treatment has not been determined. METHODS: We retrospectively examined serial serum soluble interleukin-2 receptor levels (sIL-2R) and absolute granulocyte counts in eight patients with relapsed hairy cell leukemia. All were treated with 2-CdA at the time of relapse. Serum samples were available at 3- to 6- month intervals from 5 to 9 years before relapse and 2-CdA treatment. RESULTS: sIL-2R levels increase only in patients who go on to relapse, sIL-2R levels doubled a mean of 17.1 months (range, 4-36 months) before absolute granulocyte count decreased by 50{\%}. DISCUSSION: Demonstration of a rising serum sIL-2R level in patients with hairy cell leukemia identified those with an increased risk of relapse who need more frequent observation than patients who maintain a stable sIL-2R level. Early intervention may ameliorate the toxicity of salvage therapy because disease-related neutropenia may be anticipated.",
keywords = "Disease progression, Follow-up study, Human, Lymphoproliferative malignancy, Neutropenia",
author = "Banu Arun and Curti, {Brendan D.} and Longo, {Dan L.} and Diane Stevens and Alvord, {W. Gregory} and Gause, {Barry L.} and Thelma Watson and Kopp, {William C.} and Janik, {John Edward}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "21--24",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "1",

}

TY - JOUR

T1 - Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia

AU - Arun, Banu

AU - Curti, Brendan D.

AU - Longo, Dan L.

AU - Stevens, Diane

AU - Alvord, W. Gregory

AU - Gause, Barry L.

AU - Watson, Thelma

AU - Kopp, William C.

AU - Janik, John Edward

PY - 2000/1/1

Y1 - 2000/1/1

N2 - PURPOSE: Interferon-alfa, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine (2-CdA) are effective in the management of patients with hairy cell leukemia. These agents produce remissions in most patients, but relapses occur with all three drugs. The optimal means to follow patients for relapse after treatment has not been determined. METHODS: We retrospectively examined serial serum soluble interleukin-2 receptor levels (sIL-2R) and absolute granulocyte counts in eight patients with relapsed hairy cell leukemia. All were treated with 2-CdA at the time of relapse. Serum samples were available at 3- to 6- month intervals from 5 to 9 years before relapse and 2-CdA treatment. RESULTS: sIL-2R levels increase only in patients who go on to relapse, sIL-2R levels doubled a mean of 17.1 months (range, 4-36 months) before absolute granulocyte count decreased by 50%. DISCUSSION: Demonstration of a rising serum sIL-2R level in patients with hairy cell leukemia identified those with an increased risk of relapse who need more frequent observation than patients who maintain a stable sIL-2R level. Early intervention may ameliorate the toxicity of salvage therapy because disease-related neutropenia may be anticipated.

AB - PURPOSE: Interferon-alfa, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine (2-CdA) are effective in the management of patients with hairy cell leukemia. These agents produce remissions in most patients, but relapses occur with all three drugs. The optimal means to follow patients for relapse after treatment has not been determined. METHODS: We retrospectively examined serial serum soluble interleukin-2 receptor levels (sIL-2R) and absolute granulocyte counts in eight patients with relapsed hairy cell leukemia. All were treated with 2-CdA at the time of relapse. Serum samples were available at 3- to 6- month intervals from 5 to 9 years before relapse and 2-CdA treatment. RESULTS: sIL-2R levels increase only in patients who go on to relapse, sIL-2R levels doubled a mean of 17.1 months (range, 4-36 months) before absolute granulocyte count decreased by 50%. DISCUSSION: Demonstration of a rising serum sIL-2R level in patients with hairy cell leukemia identified those with an increased risk of relapse who need more frequent observation than patients who maintain a stable sIL-2R level. Early intervention may ameliorate the toxicity of salvage therapy because disease-related neutropenia may be anticipated.

KW - Disease progression

KW - Follow-up study

KW - Human

KW - Lymphoproliferative malignancy

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0033960682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033960682&partnerID=8YFLogxK

M3 - Article

C2 - 10696734

AN - SCOPUS:0033960682

VL - 6

SP - 21

EP - 24

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 1

ER -